Cargando…

Uptake of the lateral flow urine LAM test in Europe and Central Asia

INTRODUCTION: Since 2015 (updated in 2019), the WHO has recommended to include the commercial lateral flow urine lipoarabinomannan TB test (LF-LAM), AlereLAM, in the diagnostic toolkit for severely ill people living with HIV. METHODS: To assess the current use and barriers to the implementation of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kraef, C., Yedilbayev, A., Seguy, N., Bentzon, A., Podlekareva, D., Cirillo, D. M., van der Werf, M. J., Kirk, O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Union Against Tuberculosis and Lung Disease 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423022/
https://www.ncbi.nlm.nih.gov/pubmed/35996279
http://dx.doi.org/10.5588/ijtld.21.0656
_version_ 1784777937422123008
author Kraef, C.
Yedilbayev, A.
Seguy, N.
Bentzon, A.
Podlekareva, D.
Cirillo, D. M.
van der Werf, M. J.
Kirk, O.
author_facet Kraef, C.
Yedilbayev, A.
Seguy, N.
Bentzon, A.
Podlekareva, D.
Cirillo, D. M.
van der Werf, M. J.
Kirk, O.
author_sort Kraef, C.
collection PubMed
description INTRODUCTION: Since 2015 (updated in 2019), the WHO has recommended to include the commercial lateral flow urine lipoarabinomannan TB test (LF-LAM), AlereLAM, in the diagnostic toolkit for severely ill people living with HIV. METHODS: To assess the current use and barriers to the implementation of the test, we conducted an electronic survey among national focal points and managers of TB and HIV programmes in the 53 Member States of the WHO European Region and a European network of clinicians working in TB and HIV medicine. RESULTS: In all, 45 individual responses (37 countries) were received from programme managers and focal points and 17 responses (14 countries) from clinicians. Only eight countries reported adopting LF-LAM policies, with only four currently using the AlereLAM (Armenia, Belarus, Ukraine and Uzbekistan). The most commonly reported barriers to implementing the test were the small number of eligible patients (with HIV-TB co-infections), the test not being included in the TB or HIV programme’s mandate and lack of budget allocation. CONCLUSION: Consistent with findings from high TB burden countries in Africa and Asia, the survey demonstrated that uptake of AlereLAM is almost non-existent. Addressing the identified barriers and the intrinsic limitations of the test could help to increase the use of the test.
format Online
Article
Text
id pubmed-9423022
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher International Union Against Tuberculosis and Lung Disease
record_format MEDLINE/PubMed
spelling pubmed-94230222022-09-05 Uptake of the lateral flow urine LAM test in Europe and Central Asia Kraef, C. Yedilbayev, A. Seguy, N. Bentzon, A. Podlekareva, D. Cirillo, D. M. van der Werf, M. J. Kirk, O. Int J Tuberc Lung Dis Original Articles INTRODUCTION: Since 2015 (updated in 2019), the WHO has recommended to include the commercial lateral flow urine lipoarabinomannan TB test (LF-LAM), AlereLAM, in the diagnostic toolkit for severely ill people living with HIV. METHODS: To assess the current use and barriers to the implementation of the test, we conducted an electronic survey among national focal points and managers of TB and HIV programmes in the 53 Member States of the WHO European Region and a European network of clinicians working in TB and HIV medicine. RESULTS: In all, 45 individual responses (37 countries) were received from programme managers and focal points and 17 responses (14 countries) from clinicians. Only eight countries reported adopting LF-LAM policies, with only four currently using the AlereLAM (Armenia, Belarus, Ukraine and Uzbekistan). The most commonly reported barriers to implementing the test were the small number of eligible patients (with HIV-TB co-infections), the test not being included in the TB or HIV programme’s mandate and lack of budget allocation. CONCLUSION: Consistent with findings from high TB burden countries in Africa and Asia, the survey demonstrated that uptake of AlereLAM is almost non-existent. Addressing the identified barriers and the intrinsic limitations of the test could help to increase the use of the test. International Union Against Tuberculosis and Lung Disease 2022-09 2022-09-01 /pmc/articles/PMC9423022/ /pubmed/35996279 http://dx.doi.org/10.5588/ijtld.21.0656 Text en © 2022 The Union https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
spellingShingle Original Articles
Kraef, C.
Yedilbayev, A.
Seguy, N.
Bentzon, A.
Podlekareva, D.
Cirillo, D. M.
van der Werf, M. J.
Kirk, O.
Uptake of the lateral flow urine LAM test in Europe and Central Asia
title Uptake of the lateral flow urine LAM test in Europe and Central Asia
title_full Uptake of the lateral flow urine LAM test in Europe and Central Asia
title_fullStr Uptake of the lateral flow urine LAM test in Europe and Central Asia
title_full_unstemmed Uptake of the lateral flow urine LAM test in Europe and Central Asia
title_short Uptake of the lateral flow urine LAM test in Europe and Central Asia
title_sort uptake of the lateral flow urine lam test in europe and central asia
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423022/
https://www.ncbi.nlm.nih.gov/pubmed/35996279
http://dx.doi.org/10.5588/ijtld.21.0656
work_keys_str_mv AT kraefc uptakeofthelateralflowurinelamtestineuropeandcentralasia
AT yedilbayeva uptakeofthelateralflowurinelamtestineuropeandcentralasia
AT seguyn uptakeofthelateralflowurinelamtestineuropeandcentralasia
AT bentzona uptakeofthelateralflowurinelamtestineuropeandcentralasia
AT podlekarevad uptakeofthelateralflowurinelamtestineuropeandcentralasia
AT cirillodm uptakeofthelateralflowurinelamtestineuropeandcentralasia
AT vanderwerfmj uptakeofthelateralflowurinelamtestineuropeandcentralasia
AT kirko uptakeofthelateralflowurinelamtestineuropeandcentralasia